

ABSTRACT OF THE DISCLOSURE

5 An analgesic benefit is realized by continuously
supplying a peptide in vivo that activates an opioid
receptor or that interferes with the binding of substance
P to its receptors. The long-term, continuous provision
of such a peptide can be accomplished by (a) transducing
myogenic cells with DNA expressing the peptide and
10 (b) administering the transduced myogenic cells to a
patient, such that the cells continuously produce the
peptide.

09085344-110801